Affymax Lays Out Hematide Phase III Development Plan For Anemia
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA allows firm to compare the novel artificial peptide-based ESA head-to-head with currently marketed recombinant products, a move that may bode well for EPOs in upcoming Cardio Renal panel review.
You may also be interested in...
New York Attorney General Probes Amgen Marketing Activities
Filing with Securities and Exchange Commission also reveals two shareholder legal actions against the firm.
FDA Deems Mircera “Approvable” For Anemia Pending Cardio-Renal Committee Outcome
No further clinical trials involving the long-acting erythropoiesis-stimulating agent are anticipated, Roche says.
ODAC Calls For Additional EPO Trials To Support Continued Use In Oncology
In the absence of data on approved therapeutic target, panel advises adding warnings from signals in off-label use to label.